RecruitingVaginal AtrophyAtrophic VaginitisGenitourinary Syndrome of Menopause (GSM)
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
Eligible age
18+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.
Sponsor: Stratpharma AG
You may qualify if…
- ✓ Diagnosed vaginal atrophy
- ✓ Access to smartphone and tablet, laptop or computer
- ✓ Access to a valid email address
- ✓ Previously completed laser therapy session schedule
You may not qualify if…
- ✕ Unable to provide informed consent
- ✕ Patient unable to apply topical device
- ✕ Allergy or intolerance to ingredients or excipients of the formulation of studied products
- ✕ Systemic hormonal or steroidal therapy started less than 30 days before baseline ( = not yet on a stable regimen)
Where it's recruiting
California
Laguna Hills
Source: ClinicalTrials.gov · NCT07346287 · last updated 2026-01-16